CXT vs DBD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CXT and DBD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CXT and DBD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Crane NXT, Co. makes the physical things that prove something is real and that money is money. Its Security and Authentication Technologies segment contains Crane Currency, a roughly 225-year-old business that supplies banknote paper and micro-optic security features to the US Bureau of Engraving and Printing and to central banks abroad, plus Crane Authentication, the brand-protection and government-credential unit assembled from OpSec Security and the De La Rue Authentication business bought in May 2025 for ~300 million pounds. The Detection and Traceability Technologies segment holds Crane Payment Innovations, whose bill validators, coin mechanisms and cash-recycling hardware sit inside vending machines, slot machines, self-checkout lanes and bank branches, and now Antares Vision, the Italian inspection and track-and-trace supplier acquired on April 1, 2026 and delisted from Euronext Milan. The company became a standalone issuer on April 3, 2023, when Crane Holdings separated its aerospace, industrial and process-flow operations into Crane Company (NYSE: CR) and kept the payment and security businesses under the Crane NXT name.

Full CXT guide

Diebold Nixdorf makes the machines that move cash and check out shoppers: ATMs, cash recyclers, self-checkout systems, point-of-sale terminals, and kiosks, sold through two segments (Banking and Retail) alongside the Vynamic software suite and a large installed-base services business. It is the global leader in self-checkout shipments outside China and serves a majority of the world's largest banks and retailers, so its revenue is tied to bank branch modernization, cash-recycling adoption, and retail automation cycles rather than any single fast-growing end market.

Full DBD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CXT drivers: Currency and authentication backlog at a record; The bought pivot into authentication and traceability.
• DBD drivers: Services mix and recurring revenue; DN Series recyclers and margin uplift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is that headline growth is purchased and organic growth is barely positive, so a slower integration or a missed synergy target shows up immediately in the numbers with no underlying momentum to cushion it. For DBD, the core hardware markets (ATMs, POS, self-checkout) are mature and grow at low single digits, so structural declines in cash usage and bank branch counts are a persistent headwind.

Pick CXT if you believe its drivers more; DBD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CXT and DBD guides.

CXT. Q2 2026 adjusted EPS of ~$1.10 beat consensus near ~$1.04 and management lifted the full-year adjusted EPS range while leaving sales growth at ~15% to ~17% and adjusted EBITDA margin near ~24%. Total backlog reached ~$755 million, split ~$498 million in Security and Authentication and ~$257 million in Detection and Traceability. The stock trades roughly a quarter below its ~$69 52-week high, and the low forward multiple mainly reflects the market pricing acquisition-driven earnings and ~2.7x leverage more conservatively than organic earnings.

DBD. DBD trades around a $2.9 to $3.0 billion market cap with the stock near the mid-$80s, well above its August 2023 relisting price of about $20.57. Valuation multiples reflect a re-rated turnaround: revenue growth is modest (low single digits) but free cash flow and margins have improved markedly since emergence. The reported P/E near the high-20s is elevated for a mature hardware company, so the market is pricing in continued margin and cash-flow expansion rather than top-line acceleration.

Headline figures (approximate, August 2026): CXT shows revenue (ttm) ~$1.80B, q2 2026 sales ~$493M (+22% YoY, ~+2.8% organic), fy2026 adjusted eps guidance ~$4.22 to ~$4.42, market cap ~$3.0B at ~$52 per share; DBD shows revenue (ttm) ~$3.86B, q1 2026 revenue ~$888M (+6% YoY), 2026 adj. ebitda guidance ~$510M to $535M, 2026 adj. eps guidance ~$5.25 to $5.75.

CXT and DBD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CXT and DBD exposure against your real portfolio. It is not an investment adviser.